“predisposes to pan-lymphoid malignancy syndrome associated with melanoma, sarcoma, and myeloproliferative neoplasms associated with long telemore (TL) and ageing of lymphocytes, sustaining lymphocyte clonal evolution especially in B cells. UK Biobank participants with pathogenic POT1 variants had long TL and higher lymphoid malignancy rates (45% by the age of 80 years; hazard ratio, 8.28; 95% confidence interval, 5.29-13.0). Haploinsufficient mutations in POT1 lead to an autosomal dominant cancer-prone syndrome mediated by long TL.7,13-15 POT1 binds single-stranded telomeric DNA and is essential for telomere protection,16 but POT1 heterozygous loss of function is permissive of telomerase elongation in the absence of a detectable DNA damage response. The prevalence of POT1 mutations in cancer has been limited to single-disease studies, and mutations have been identified consistently in ∼0.5% to 1% of multiple cancers.”
7)